NasdaqGS:BBIOBiotechs
A Look At BridgeBio Pharma (BBIO) Valuation After New ATTR-CM, LGMD2I/R9 And TTR Antibody Updates
Why BridgeBio Pharma stock is back in focus
BridgeBio Pharma (BBIO) has returned to the spotlight after management outlined fresh clinical and commercial milestones around its ATTR-CM franchise, the FORTIFY Phase 3 program in LGMD2I/R9, and a new TTR amyloid depleter antibody effort.
For investors, the combination of growing real-world use of acoramidis, FDA feedback on a potential full approval filing for BBP-418, and the planned TTR antibody program creates a fuller picture of BridgeBio’s...